Specialty Pharmacy

The interchangeability designation demonstrates that the efficacy and safety of a biosimilar is equal to the reference product.

With the entrance of more effective and less costly drugs, older treatments will likely decrease.

MicroRNAs could monitor the severity of MS in the future.

Common diabetes drug changes the biology of cancer cells.

Time of day is an important factor in chemotherapy-induced adverse events.

Pro-inflammatory cervicovaginal bacteria increased HIV risk more than 4-fold in women.

Top news of the day from across the health care landscape.

While nephrotoxicity associated with TDF has been well documented, prospective studies in HIV patients have been lacking.

The FDA recently accepted 2 new supplemental biologics license applications from Merck for pembrolizumab (Keytruda) in patients with bladder cancer.

Direct and indirect remuneration fees seen to increase costs for Medicare, beneficiaries, pharmacies, and taxpayers.

Study finds direct and indirect remuneration fees increase healthcare costs.

Smoking is a risk factor for breaking tolerance to multiple autoantigens in RA.

Findings may lead to preventative treatments for breast cancer, such as anti-inflammatory drugs.

HCV rates 3 times higher in patients with lupus.

Top news of the day from across the health care landscape.

African American women account for 62% of women diagnosed with HIV.

Top news of the week in oncology and cancer drug development.

Ocrelizumab may effectively treat patients with relapsing multiple sclerosis and primary progressive multiple sclerosis.

Top articles of the week from Specialty Pharmacy Times.

Ninety-three percent of women reported at least 1 adverse event from breast cancer treatment.

Scientists used a novel approach for imaging the movement of immune cells in mouse models of RA.

Immunotherapy also found to prolong life in patients with bladder cancer.

Young and middle-aged adults with colon cancer are 2 to 8 times more likely to receive postoperative chemotherapy.

Computer algorithm for skin cancer matched performance of human dermatologists.

Cancer may be stopped by depriving cells of vital nutrients.

Repetitive transcranial magnet stimulation shows promise treating symptoms of MS.

Application pulled for biosimilar that treats neutropenia.

Congress, regulators, and the media expected to place pressure on pharmacy benefit managers in the coming months.